M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction

Not Applicable

Active, not recruiting

Conditions: Breast Carcinoma

Interventions: Other: Enhanced Consultation
Other: Standard of Care Consultation
Procedure: Conventional Imaging
Other: Educational Intervention
Other: Questionnaire Administration

First Posted Date: 2021-11-23

Last Posted Date: 2024-03-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT05130580

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

GRAvity- Versus Wall Suction-drIven Large Volume Thoracentesis: a rAndomized Controlled Study (GRAWITAS Study)

Not Applicable

Recruiting

Conditions: Pleural Effusions, Chronic
Pulmonary Edema
Thoracentesis

Interventions: Other: Standard Suction Thoracentesis
Other: Gravity Thoracentesis

First Posted Date: 2021-11-23

Last Posted Date: 2024-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 228

Registration Number: NCT05131945

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

Completed

Conditions: Anal Squamous Cell Carcinoma
Stage IIB Anal Cancer AJCC v8
Stage IIIC Anal Cancer AJCC v8
Stage IIA Anal Cancer AJCC v8
Stage IIIB Anal Cancer AJCC v8
Stage I Anal Cancer AJCC v8
Stage III Anal Cancer AJCC v8
Stage 0 Anal Cancer AJCC v8
Stage II Anal Cancer AJCC v8
Stage IIIA Anal Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Other: Electronic Health Record Review
Procedure: Follow-Up
Procedure: Positron Emission Tomography

First Posted Date: 2021-11-22

Last Posted Date: 2024-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 41

Registration Number: NCT05130073

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

3D Printed Oral Stents for Patients with Head and Neck Cancer Receiving Radiation Therapy

Not Applicable

Active, not recruiting

Conditions: Malignant Head and Neck Neoplasm

Interventions: Other: Questionnaire Administration
Device: Stent Device

First Posted Date: 2021-11-19

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 57

Registration Number: NCT05126797

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling

Recruiting

Conditions: Li-Fraumeni Syndrome

Interventions: Other: Questionnaire Administration

First Posted Date: 2021-11-19

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 500

Registration Number: NCT05126810

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

Not Applicable

Suspended

Conditions: Cancer
Diabetes

Interventions: Other: Fitbit
Other: Continuous Glucose Monitor

First Posted Date: 2021-11-18

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT05124405

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Phase 2

Recruiting

Conditions: Ovarian Cancer

Interventions: Other: Cytoreductive surgery

First Posted Date: 2021-11-17

Last Posted Date: 2024-10-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05123807

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Phase 1

Withdrawn

Conditions: Brain Tumor

Interventions: Drug: tepotinib
Drug: tepotinib plus osimertinib

First Posted Date: 2021-11-16

Last Posted Date: 2024-04-17

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05120960

A Phase II Study of Neoadjuvant Sotorasib in Combination with Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer with a KRAS P.G12C Mutation

Phase 2

Recruiting

Conditions: Lung Cancer

Interventions: Drug: AMG 510
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2021-11-12

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT05118854

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Single Step Lesion Annotation and Localization of Suspicious Breast Lesions

Early Phase 1

Recruiting

Conditions: Breast Lesions

Interventions: Device: SAVI Scout®

First Posted Date: 2021-11-11

Last Posted Date: 2024-07-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05118295

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy